Newsmaker: Constellation Pharmaceuticals.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 20944577.
- Also identified by DOI 10.1038/nbt1010-997.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Replete with investor funds, the Cambridge, Massachusetts–based epigenetics firm is taking aim at methylases anddemethylases linked to disease.
Medical subject headings
- Drug Industry